Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluar la seguridad y eficacia de las células madre mesenquimales del cordón umbilical alogénico en pacientes con COVID-19 (UMSC01)

21 de septiembre de 2026 actualizado por: Ever Supreme Bio Technology Co., Ltd.

Un estudio clínico de fase I/IIa continuo para evaluar la seguridad y la eficacia de las células madre mesenquimales alogénicas del cordón umbilical en pacientes con enfermedad grave y crítica de COVID-19

This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration. The novelty of the current UMSC01 treatment is the single IV infusion of UMSC01 to the worldwide emergency outbreaks of COVID-19. We hypothesize that sufficient UMSC01 retention in lung may modulate the systemic inflammatory responses.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The lead Phase I safety phase will further confirm the safety profile of UMSC01 in 5 COVID-19 patients each at two dose regimens and placebo.

To start the Phase IIa study, data analysis will be performed as soon as the 21-day treatment period has been completed in the three groups. With considerations of the pandemic status and clinical practice, only one of the two active treatment groups will be selected to complete the Phase IIa study, which will recruit 60 patients.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

75

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Non-US
      • Taichung, Non-US, Taiwán, 404
        • China Medical University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female aged 20 to 80 years old.

  2. Hospitalized severe and critical COVID-19 patients with laboratory confirmation by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal/ oropharyngeal samples collected using standardized method.

  3. Pneumonia or interstitial lung damage that is confirmed by chest radiographs or computed tomography.

  4. Severe COVID-19 infection which meets any one of the following: 1) dyspnea (PR ≥ 30 times/min), 2) finger oxygen saturation ≤ 93% in the room air and resting state, 3) arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300 mmHg, 4) pulmonary imaging which shows that the focus progress > 50% within 24-48 hours, or

  5. Critically severe COVID-19 infection which meets any of the following: 1) respiratory failure treated by mechanical ventilation, 2) shock, 3) combined with other organ failure, 4) patients expected to need ICU monitoring and treatment.

  6. High sensitivity C-reactive protein (hs-CRP) serum level > 4.0 mg/dL.

  7. All female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) shown below, for at least 4 weeks after UMSC01 treatment and agree to maintain such contraceptive method(s) for another 4 weeks after UMSC01 treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    2. Female sterilization (bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, the reproductive status of the woman should be confirmed by the hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject.
    4. Combination of any two of the following listed methods: (d.1 + d.2 or d.1 + d.3, or d.2 + d.3):

    d.1 Use of oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), such as hormone vaginal ring or transdermal hormone contraception.

    d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Exclusion Criteria:

  1. Pregnancy, lactation, and those who are not pregnant but did not, or unwilling to, take effective contraceptives measures 4 weeks before and after the treatment.
  2. Patients with malignant tumors or other serious systemic diseases.
  3. Patients with hemoglobin < 10 g, alanine aminotransferase (ALT) ≥ 5 × ULN, aspartate aminotransferase (AST) ≥ 5 × ULN, alkaline phosphatase (ALP) ≥ 5 × ULN, total bilirubin (TBILI) ≥ 2 × ULN, serum creatinine > 2.5 mg/dl, platelet counts < 100,000/μL, WBC < 3,000 cells/μL, or neutrophil counts < 1,000/μL at screening.
  4. Presence of barotrauma or hemodynamic instability defined as hypotension with diastolic blood pressure < 90 mmHg or mean arterial pressure (MAP) < 70 mmHg despite fluid expansion, and vasoactive support or pneumothorax at screening.
  5. Uncontrolled hypertension with systolic blood pressure > 170 mmHg and diastolic blood pressure > 100 mmHg which, in the investigator's judgment, would not make participation appropriate.
  6. Recent history of (within 2 years) ischemic heart disease or cerebrovascular attack, such as myocardial infarction, unstable angina, or stroke.
  7. Recent history (within 2 years) of hypercoagulable disorder, antiphospholipid syndrome, pulmonary embolism, or deep venous thrombosis.
  8. Condition other than COVID-19 that is projected to limit lifespan to ≤ 1 year.
  9. History of drug or alcohol abuse within the past 24 months.
  10. Unwilling to commit to follow-up visits.
  11. Patients who are participating in other clinical trials with an investigational product.
  12. Co-infection of HIV, tuberculosis, influenza virus, adenovirus, and other respiratory infection virus.
  13. Patients with other conditions that are not suitable to participate in this clinical study as determined by the investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: UMSC01

UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.

UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

Comparador de placebos: Placebo

Normal saline will be administered to patients after COVID-19 infection.

Normal saline will be IV infusion with 12 months of follow up after treatment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Two Co-Primary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Proportion of patients alive with sustained improvement within the 21 days of the treatment period (Proportion Analysis), which indicates the capability of UMSC01 to save more lives

21 days of the treatment period
Two Co-Primary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Time (days) to reach sustained improvement within the 21 days of the treatment period (Time-to-Event Analysis), which indicates the capability of UMSC01 to enable patients to less suffer from the disease condition.

21 days of the treatment period

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Proportion of enrolled patients alive on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Proportion of enrolled patients alive and free of respiratory failure on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Improvement of COVID 19 pneumonia confirmed by chest radiographs or computed tomography on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Improvement of clinical symptoms including duration of fever in degrees C and respiratory failure on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Duration of ventilator usage or oxygen therapy on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Levels of tumor necrosis factor-alpha (TNF-α) in pg/ml, interleukin-6 (IL-6) in pg/ml and interleukin-10 (IL-10) in pg/ml, and C-reactive protein (hsCRP) in mg/dl on Day 21 or on the day of discharge compared to baseline

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Troponin I level as assessed via serum blood samples on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

ICU admission rate on Day 21 or on the day of discharge with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 14 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 14 compared with historical data

14 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 21 compared with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: through study completion, an average of 1 year

Average time (days) for which the patients are alive and free of respiratory failure during the treatment period

through study completion, an average of 1 year
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Proportion of patients who need ICU care on Day 21 based on the clinical indicative of admission to ICU

21 days of the treatment period
Secondary Efficacy Endpoints
Periodo de tiempo: 21 days of the treatment period

Proportion of patients who has been discharged form hospital on Day 21

21 days of the treatment period
Secondary Safety Endpoints
Periodo de tiempo: 21 days of the treatment period

Number of Participants with infusion-related and allergic reactions during the treatment period

21 days of the treatment period
Secondary Safety Endpoints
Periodo de tiempo: through study completion, an average of 1 year

Secondary infection, treatment emergent adverse event (TEAE), serious adverse event (SAE), and suspected and unexpected serious adverse reaction (SUSAR) incidences over the study period. The toxicities will be assessed by CTCAE V5.0 during the whole study period (380 days)

through study completion, an average of 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Woei C Shyu, Ever Supreme Bio Technology Co., Ltd.
  • Investigador principal: Long Bin Jeng, China Medical University Hospital

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de agosto de 2020

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de agosto de 2022

Primero enviado que cumplió con los criterios de control de calidad

11 de agosto de 2022

Publicado por primera vez (Actual)

15 de agosto de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ES-CMSC01-C1101

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .